Author

Vicki Jardine

Observed names: V. Jardine, V.L. Jardine, Vicki L. Jardine

Observed institution: Bayer (United Kingdom)

OpenAlex ID: A5050801220

How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

2024 · Ana P. Kiess, Joseph O'Donoghue, et al. · Journal of Clinical Oncology · 36

Targeted thorium-227 conjugates as treatment options in oncology

2023 · Jenny Karlsson, Christoph A. Schatz, et al. · Frontiers in Medicine · 32

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen–Targeted 212 Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer

2025 · Kjetil Berner, Eivor Hernes, et al. · Journal of Nuclear Medicine · 22

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors

2025 · A. Minchom, O. Lindén, et al. · ESMO Open · 8

The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.

2026 · Sandra P. D'Angelo, William D. Tap, et al. · Journal of Clinical Oncology · 1

2542eTiP Phase I/II dose escalation and expansion of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC): The ARTISAN trial

2025 · O. Sartor, J.S. de Bono, et al. · Annals of Oncology · 1

P102 First-in-human study of AB001, a prostate-specific membrane antigen (PSMA) targeted 212Pb alpha radioligand, in patients with metastatic castration resistant prostate cancer (mCRPC): Phase 0 experience

2024 · K. Berner, E. Hernes, et al. · European Urology Open Science · 1

Normal-Organ Absorbed Dose and Response Assessment in α-Particle Radiopharmaceutical Therapy

2026 · Jacob Y. Hesterman, Robert F. Hobbs, et al. · Journal of Nuclear Medicine

Works count: 8

Citation count: 101

H-index: 4

I10-index: 3